Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease

被引：1134

作者：

Dai, Wenhao ^{[1
,2
]}

Zhang, Bing ^{[3
,4
]}

Jiang, Xia-Ming ^{[5
]}

Su, Haixia ^{[1
,6
]}

Li, Jian ^{[1
,6
]}

Zhao, Yao ^{[3
,4
]}

Xie, Xiong ^{[1
,6
]}

Jin, Zhenming ^{[3
,4
]}

Peng, Jingjing ^{[1
,6
]}

Liu, Fengjiang ^{[3
,4
]}

Li, Chunpu ^{[1
,6
]}

Li, You ^{[8
]}

Bai, Fang ^{[3
,4
]}

Wang, Haofeng ^{[3
,4
]}

Cheng, Xi ^{[1
]}

Cen, Xiaobo ^{[8
]}

Hu, Shulei ^{[1
]}

Yang, Xiuna ^{[3
,4
]}

Wang, Jiang ^{[1
,6
]}

Liu, Xiang ^{[9
]}

Xiao, Gengfu ^{[5
]}

Jiang, Hualiang ^{[1
,3
,4
,6
]}

Rao, Zihe ^{[3
,4
]}

Zhang, Lei-Ke ^{[5
]}

Xu, Yechun ^{[1
,6
]}

Yang, Haitao ^{[3
,4
]}

Liu, Hong ^{[1
,2
,6
,7
]}

机构：

[1] Chinese Acad Sci, Shanghai Inst Mat Med, CAS Key Lab Receptor Res, State Key Lab Drug Res, Shanghai 201203, Peoples R China

[2] China Pharmaceut Univ, Sch Pharm, Nanjing 210009, Jiangsu, Peoples R China

[3] ShanghaiTech Univ, Shanghai Inst Adv Immunochem Studies, Shanghai 201210, Peoples R China

[4] ShanghaiTech Univ, Sch Life Sci & Technol, Shanghai 201210, Peoples R China

[5] Chinese Acad Sci, Ctr Biosafety Mega Sci, Wuhan Inst Virol, State Key Lab Virol, Wuhan 430071, Peoples R China

[6] Univ Chinese Acad Sci, Beijing 100049, Peoples R China

[7] Nanjing Univ Chinese Med, Coll Pharm, Nanjing 210023, Peoples R China

[8] Sichuan Univ, Westchina Hosp, Natl Chengdu Ctr Safety Evaluat Drugs, Chengdu 610041, Sichuan, Peoples R China

[9] Nankai Univ, State Key Lab Med Chem Biol, Frontiers Sci Ctr Cell Response, Coll Pharm,Coll Life Sci, Tianjin 300353, Peoples R China

来源：

SCIENCE | 2020年 / 368卷 / 6497期

基金：

中国国家自然科学基金;

关键词：

CORONAVIRUS; INHIBITORS; 3C;

D O I：

10.1126/science.abb4489

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) is the etiological agent responsible for the global COVID-19 (coronavirus disease 2019) outbreak. The main protease of SARS-CoV-2, M-pro, is a key enzyme that plays a pivotal role in mediating viral replication and transcription. We designed and synthesized two lead compounds (11a and 11b) targeting M-pro. Both exhibited excellent inhibitory activity and potent anti-SARS-CoV-2 infection activity. The x-ray crystal structures of SARS-CoV-2 M-pro in complex with 11a or 11b, both determined at a resolution of 1.5 angstroms, showed that the aldehyde groups of 11a and 11b are covalently bound to cysteine 145 of M-pro. Both compounds showed good pharmacokinetic properties in vivo, and 11a also exhibited low toxicity, which suggests that these compounds are promising drug candidates.

引用

页码：1331 / +

页数：35

共 50 条

[31] Identification of prospective covalent inhibitors for SARS-CoV-2 main protease using structure-based approach
Gayatri, Shenvi Kudchadker
Chhabra, Vaishnavi
Kumar, Harish
Sobhia, M. Elizabeth
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2023, 41 (16): : 7913 - 7930
[32] Identification of key interactions between SARS-CoV-2 main protease and inhibitor drug candidates
Ryunosuke Yoshino
Nobuaki Yasuo
Masakazu Sekijima
Scientific Reports, 10
[33] Identification of key interactions between SARS-CoV-2 main protease and inhibitor drug candidates
Yoshino, Ryunosuke
Yasuo, Nobuaki
Sekijima, Masakazu
SCIENTIFIC REPORTS, 2020, 10 (01)
[34] Structure-Based Virtual Screening to Discover Potential Lead Molecules for the SARS-CoV-2 Main Protease
Gahlawat, Anuj
Kumar, Navneet
Kumar, Rajender
Sandhu, Hardeep
Singh, Inder Pal
Singh, Saranjit
Sjostedt, Anders
Garg, Prabha
JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2020, 60 (12) : 5781 - 5793
[35] Evaluation of Clove Phytochemicals as Potential Antiviral Drug Candidates Targeting SARS-CoV-2 Main Protease: Computational Docking, Molecular Dynamics Simulation, and Pharmacokinetic Profiling
Manivannan, Arun Chandra
Malaisamy, Arunkumar
Eswaran, Murugesh
Meyyazhagan, Arun
Arumugam, Vijaya Anand
Rengasamy, Kannan R. R.
Balasubramanian, Balamuralikrishnan
Liu, Wen-Chao
FRONTIERS IN MOLECULAR BIOSCIENCES, 2022, 9
[36] Structure-Based Design of Covalent SARS-CoV-2 Papain-like Protease Inhibitors
Tan, Bin
Liang, Xueying
Ansari, Ahmadullah
Jadhav, Prakash
Tan, Haozhou
Li, Kan
Ruiz, Francesc Xavier
Arnold, Eddy
Deng, Xufang
Wang, Jun
JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (22) : 20399 - 20420
[37] Design and Evaluation of Peptide Inhibitors Targeting the Dimerization of SARS-CoV-2 Main Protease
Yang, Yi
Zhao, Zhiyi
Li, Xiaoying
Chen, Yian
Liu, Lu
Zhang, Shao-Lin
Yang, Aimin
CHEMBIOCHEM, 2025, 26 (01)
[38] Structure-based drug design of an inhibitor of the SARS-CoV-2 (COVID-19) main protease using free software: A tutorial for students and scientists
Zhang, Sheng
Krumberger, Maj
Morris, Michael A.
Parrocha, Chelsea Marie T.
Kreutzer, Adam G.
Nowick, James S.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2021, 218
[39] Structure-based design and synthesis of copper(II) complexes as antivirus drug candidates targeting SARS CoV-2 and HIV
Kumar, Sunil
Choudhary, Mukesh
NEW JOURNAL OF CHEMISTRY, 2022, 46 (15) : 7128 - 7143
[40] Impact of Drug Repurposing on SARS-Cov-2 Main Protease
Ndagi, Umar
Abdullahi, Maryam
Hamza, Asmau N. N.
Magaji, Mohd G. G.
Mhlongo, Ndumiso N. N.
Babazhitsu, Makun
Majiya, Hussaini
Makun, Hussaini Anthony
Lawal, Monsurat M. M.
RUSSIAN JOURNAL OF PHYSICAL CHEMISTRY A, 2022, 96 (14) : 3311 - 3330

← 1 2 3 4 5 →